In this webinar, the BioNTech US team presents data on their study of peripheral blood cells from metastatic melanoma patients before, during, and after treatment with personalized neoantigen therapy plus anti-PD-1. By combining T cell receptor repertoire profiling and immunophenotyping, the team found that analyzing blood cells collected pre-treatment presents a strong predictor for response to treatment in a minimally invasive manner.
Highlights
Pre-treatment blood-based factors predict response to neoantigen + anti-PD-1 combination
TCR repertoire clonality and stability correlate with improved clinical outcomes
Baseline T and B cell memory phenotypes associate with improved clinical outcomes
Combined baseline TCR repertoire and PBMC phenotypes predict immunotherapy response
Personalized neoantigen vaccines are designed based on patient and tumor-specific mutations that aim to drive effective anti-tumor immunity. This treatment modality has been combined with checkpoint inhibitors in the clinic. Unfortunately, as with many current immunotherapies, not all patients respond to this combined treatment. Identifying patients most likely to respond positively to treatment during clinical trial enrollment may assist with patient stratification and medical decision-making.
